Ziconotide (PrialtĀ®) for the intrathecal treatment of severe, chronic pain

All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000442
Authors' recomendations: Ziconotide (Prialt) is not recommended for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia. Key factor influencing the recommendation: The case for cost effectiveness of ziconotide (Prialt) has not been proven.
Project Status: Completed
Year Published: 2008
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Analgesics, Non-Narcotic
  • Pain
  • Chronic Disease
  • Injections, Spinal
  • omega-Conotoxins
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.